Streetbeat News

Products Services

AAPL

Apple shares fell in premarket trading due to lower-than-expected iPhone 16 preorders, competition in China, and broader market concerns. Analyst Ming-Chi Kuo reported a 12.7% drop in preorders compared to the iPhone 15, citing weak demand for the Pro series and competition from Huawei.

Portfolio Pulse from Shanthi Rexaline

September 16, 2024 | 11:17 am

BYSI

Beyondspring presented final data on the Dublin-3 study at the European Society for Medical Oncology, focusing on safety outcomes for 2L/3L EGFR wild-type NSCLC. Despite severe neutropenia associated with docetaxel, it remains the standard of care. Recent studies have not shown significant overall survival benefits over docetaxel.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:16 am

TECH

ScaleReady and Bio-Techne have launched the G-Rex Optimized ProPak GMP Cytokines, designed for high-efficiency closed system cell and gene-modified cell therapy manufacturing. This product aims to enhance the manufacturing process in the biotech industry.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:14 am

CGEM

Cullinan Therapeutics has submitted an Investigational New Drug (IND) application to the FDA for its CD19xCD3 bispecific T cell engager, CLN-978, aimed at treating systemic lupus erythematosus.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:12 am

TNXP

Tonix Pharmaceuticals announced that the World Health Organization's preferred target product profile aligns with the characteristics of their TNX-801 vaccine, which is being developed to prevent Mpox. This alignment could potentially enhance the vaccine's marketability and acceptance.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:11 am

CANF

The Israeli Ministry of Health has approved Can-Fite Biopharma's Phase 2A clinical trial for Namodenoson, an orally-administered drug, in the treatment of pancreatic carcinoma. The study will focus on establishing the safety and clinical efficacy of the drug.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:09 am

ZNTL

Zentalis Pharmaceuticals announced that it is on track to meet its previously disclosed data guidance for the rest of 2024. The company plans to present data on azenosertib monotherapy and provide updates on its clinical development at a corporate event later this year.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:08 am

THAR

Tharimmune, Inc. has partnered with Intract Pharma to develop an oral version of infliximab, a TNF-α inhibitor, for autoimmune diseases. This collaboration aims to improve patient compliance and expand Tharimmune's therapeutic pipeline.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:08 am

ASND

Ascendis Pharma released positive topline data from the ApproaCH trial for Transcon CNP, showing improved growth velocity in children with achondroplasia compared to placebo.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:08 am

ZNTL

Zentalis Pharmaceuticals announced that the FDA has lifted the partial clinical hold on its azenosertib studies, allowing the company to resume enrollment in all ongoing clinical trials without changes to the development plan.

Portfolio Pulse from Benzinga Newsdesk

September 16, 2024 | 11:08 am